Startseite Should phosphatidylethanol be currently analysed using whole blood, dried blood spots or both?
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Should phosphatidylethanol be currently analysed using whole blood, dried blood spots or both?

  • Van Long Nguyen EMAIL logo und Michael Fitzpatrick
Veröffentlicht/Copyright: 11. Oktober 2018
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Clinical Chemistry and Laboratory Medicine (CCLM)
Aus der Zeitschrift Clinical Chemistry and Laboratory Medicine (CCLM) Band 57 Heft 5

Abstract

Phosphatidylethanol (PEth) are phospholipids produced through non-oxidative ethanol metabolism. They accumulate in red blood cells and have been traditionally analysed in whole blood as potential biomarkers for moderate to long-term alcohol consumption. More recently, their analysis in dried blood spots has been gaining favour, namely, due to the ease in sampling, transport and storage conditions required. This paper aims at providing a short comparative review between analysing PEth in whole blood and dried blood spots and the potential pitfalls that researchers may face when setting up PEth testing for clinical use.

Keywords: alcohol; dried blood spot; phosphatidylethanol; whole blood

Acknowledgments

The authors would like to acknowledge the members of staff at Chemical Pathology at Royal Prince Alfred Hospital with special mentions to the director, Associate Professor David Sullivan, and the Laboratory Manager, Robert McQuilty.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Varga A, Alling C. Formation of phosphatidylethanol in vitro in red blood cells from healthy volunteers and chronic alcoholics. J Lab Clin Med 2002;140:79–83.10.1016/S0022-2143(02)00021-5Suche in Google Scholar

2. Aradóttir S, Moller K, Alling C. Phosphatidylethanol formation and degradation in human and rat blood. Alcohol Alcohol 2004;39:8–13.10.1093/alcalc/agh003Suche in Google Scholar

3. Viel G, Boscolo-Berto R, Cecchetto G, Fais P, Nalesso A, Ferrara SD. Phosphatidylethanol in blood as a marker of chronic alcohol use: a systematic review and meta-analysis. Int J Mol Sci 2012;13:14788–812.10.3390/ijms131114788Suche in Google Scholar

4. Gunnarsson T, Karlsson A, Hansson P, Johnson G, Alling C, Odham G. Determination of phosphatidylethanol in blood from alcoholic males using high-performance liquid chromatography and evaporative light scattering or electrospray mass spectrometric detection. J Chromatogr B Biomed Sci Appl 1998;705:243–9.10.1016/S0378-4347(97)00541-0Suche in Google Scholar

5. Aradóttir S, Asanovska G, Gjerss S, Hansson P, Alling C. PHosphatidylethanol (PEth) concentrations in blood are correlated to reported alcohol intake in alcohol-dependent patients. Alcohol Alcohol 2006;41:431–7.10.1093/alcalc/agl027Suche in Google Scholar PubMed

6. Gnann H, Engelmann C, Skopp G, Winkler M, Auwärter V, Dresen S, et al. Identification of 48 homologues of phosphatidylethanol in blood by LC-ESI-MS/MS. Anal Bioanal Chem 2010;396:2415–23.10.1007/s00216-010-3458-5Suche in Google Scholar PubMed

7. Zheng Y, Beck O, Helander A. Method development for routine liquid chromatography-mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in blood. Clin Chim Acta 2011;412:1428–35.10.1016/j.cca.2011.04.022Suche in Google Scholar PubMed

8. Nalesso A, Viel G, Cecchetto G, Mioni D, Pessa G, Favretto D, et al. Quantitative profiling of phosphatidylethanol molecular species in human blood by liquid chromatography high resolution mass spectrometry. J Chromatogr A 2011;1218:8423–31.10.1016/j.chroma.2011.09.068Suche in Google Scholar PubMed

9. Gnann H, Weinmann W, Thierauf A. Formation of phosphatidylethanol and its subsequent elimination during an extensive drinking experiment over 5 days. Alcohol Clin Exp Res 2012;36:1507–11.10.1111/j.1530-0277.2012.01768.xSuche in Google Scholar PubMed

10. Schröck A, Thierauf-Emberger A, Schürch S, Weinmann W. Phosphatidylethanol (PEth) detected in blood for 3 to 12 days after single consumption of alcohol-a drinking study with 16 volunteers. Int J Legal Med 2017;131:153–60.10.1007/s00414-016-1445-xSuche in Google Scholar PubMed

11. Stewart SH, Koch DG, Willner IR, Anton RF, Reuben A. Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with chronic liver disease. Alcohol Clin Exp Res 2014;38:1706–11.10.1111/acer.12442Suche in Google Scholar PubMed PubMed Central

12. Ingall GB. Alcohol biomarkers. Clin Lab Med 2012;32:391–406.10.1016/j.cll.2012.06.003Suche in Google Scholar PubMed

13. Nanau RM, Neuman MG. Biomolecules and biomarkers used in diagnosis of alcohol drinking and in monitoring therapeutic interventions. Biomolecules 2015;5:1339–85.10.3390/biom5031339Suche in Google Scholar PubMed PubMed Central

14. Gnann H, Weinmann W, Engelmann C, Wurst FM, Skopp G, Winkler M, et al. Selective detection of phosphatidylethanol homologues in blood as biomarkers for alcohol consumption by LC-ESI-MS/MS. J Mass Spectrom 2009;44:1293–9.10.1002/jms.1608Suche in Google Scholar PubMed

15. Helander A, Zheng Y. Molecular species of the alcohol biomarker phosphatidylethanol in human blood measured by LC-MS. Clin Chem 2009;55:1395–405.10.1373/clinchem.2008.120923Suche in Google Scholar PubMed

16. Cabarcos P, Ángel Cocho J, Moreda A, Míguez M, Jesús Tabernero M, Fernández P, et al. Application of dispersive liquid-liquid microextraction for the determination of phosphatidylethanol in blood by liquid chromatography tandem mass spectrometry. Talanta 2013;111:189–95.10.1016/j.talanta.2013.03.008Suche in Google Scholar PubMed

17. Isaksson A, Walther L, Hansson T, Andersson A, Stenton J, Blomgren A. High-throughput LC-MS/MS method for determination of the alcohol use biomarker phosphatidylethanol in clinical samples by use of a simple automated extraction procedure — preanalytical and analytical conditions. J Appl Lab Med 2018;2:880–92.10.1373/jalm.2017.024828Suche in Google Scholar PubMed

18. Faller A, Richter B, Kluge M, Koenig P, Seitz HK, Skopp G. Stability of phosphatidylethanol species in spiked and authentic whole blood and matching dried blood spots. Int J Legal Med 2013;127:603–10.10.1007/s00414-012-0799-ySuche in Google Scholar PubMed

19. Aradóttir S, Seidl S, Wurst FM, Jönsson BA, Alling C. Phosphatidylethanol in human organs and blood: a study on autopsy material and influences by storage conditions. Alcohol Clin Exp Res 2004;28:1718–23.10.1097/01.ALC.0000145687.41646.E5Suche in Google Scholar

20. Jain J, Evans JL, Briceño A, Page K, Hahn JA. Comparison of phosphatidylethanol results to self-reported alcohol consumption among young injection drug users. Alcohol Alcohol 2014;49:520–4.10.1093/alcalc/agu037Suche in Google Scholar PubMed PubMed Central

21. Papas RK, Gakinya BN, Mwaniki MM, Keter AK, Lee H, Loxley MP, et al. Associations between the phosphatidylethanol alcohol biomarker and self-reported alcohol use in a sample of HIV-infected outpatient drinkers in Western Kenya. Alcohol Clin Exp Res 2016;40:1779–87.10.1111/acer.13132Suche in Google Scholar PubMed PubMed Central

22. Bakhireva LN, Leeman L, Savich RD, Cano S, Gutierrez H, Savage DD, et al. The validity of phosphatidylethanol in dried blood spots of newborns for the identification of prenatal alcohol exposure. Alcohol Clin Exp Res 2014;38:1078–85.10.1111/acer.12349Suche in Google Scholar PubMed PubMed Central

23. Piano MR, Tiwari S, Nevoral L, Phillips SA. Phosphatidylethanol levels are elevated and correlate strongly with AUDIT scores in young adult binge drinkers. Alcohol Alcohol 2015;50:519–25.10.1093/alcalc/agv049Suche in Google Scholar PubMed

24. Fleming MF, Smith MJ, Oslakovic E, Lucey MR, Vue JX, Al-Saden P, et al. Phosphatidylethanol (PEth) detects moderate to heavy alcohol use in liver transplant recipients. Alcohol Clin Exp Res 2017;41:857–62.10.1111/acer.13353Suche in Google Scholar PubMed PubMed Central

25. Zakaria R, Allen KJ, Koplin JJ, Roche P, Greaves RF. Advantages and challenges of dried blood spot analysis by mass spectrometry across the total testing process. J Int Fed Clin Chem 2016;27:288–317.Suche in Google Scholar

26. Jones J, Jones M, Plate C, Lewis D. The detection of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol in human dried blood spots. Anal Methods 2011;3:1101–6.10.1039/c0ay00636jSuche in Google Scholar

27. Faller A, Richter B, Kluge M, Koenig P, Seitz HK, Thierauf A, et al. LC-MS/MS analysis of phosphatidylethanol in dried blood spots versus conventional blood specimens. Anal Bioanal Chem 2011;401:1163–6.10.1007/s00216-011-5221-ySuche in Google Scholar PubMed

28. Kummer N, Ingels AS, Wille SM, Hanak C, Verbanck P, Lambert WE, et al. Quantification of phosphatidylethanol 16:0/18:1, 18:1/18:1, and 16:0/16:0 in venous blood and venous and capillary dried blood spots from patients in alcohol withdrawal and control volunteers. Anal Bioanal Chem 2016;408:825–38.10.1007/s00216-015-9169-1Suche in Google Scholar PubMed

29. Chace DH, De Jesús VR, Spitzer AR. Clinical chemistry and dried blood spots: increasing laboratory utilization by improved understanding of quantitative challenges. Bioanalysis 2014;6:2791–4.10.4155/bio.14.237Suche in Google Scholar PubMed PubMed Central

30. Abu-Rabie P, Denniff P, Spooner N, Chowdhry BZ, Pullen FS. Investigation of different approaches to incorporating internal standard in DBS quantitative bioanalytical workflows and their effect on nullifying hematocrit-based assay bias. Anal Chem 2015;87:4996–5003.10.1021/acs.analchem.5b00908Suche in Google Scholar PubMed

31. Denniff P, Spooner N. Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis. Anal Chem 2014;86:8489–95.10.1021/ac5022562Suche in Google Scholar PubMed

32. Beck O, Kenan Modén N, Seferaj S, Lenk G, Helander A. Study of measurement of the alcohol biomarker phosphatidylethanol (PEth) in dried blood spot (DBS) samples and application of a volumetric DBS device. Clin Chim Acta 2018;479:38–42.10.1016/j.cca.2018.01.008Suche in Google Scholar PubMed

33. Hall EM, Flores SR, De Jesús VR. Influence of hematocrit and total-spot volume on performance characteristics of dried blood spots for newborn screening. Int J Neo Screen 2015;1:69–78.10.3390/ijns1020069Suche in Google Scholar PubMed PubMed Central

34. Lawson AJ, Bernstone L, Hall SK. Newborn screening blood spot analysis in the UK: influence of spot size, punch location and haematocrit. J Med Screening 2016;23:7–16.10.1177/0969141315593571Suche in Google Scholar PubMed

35. De Kesel PM, Sadones N, Capiau S, Lambert WE, Stove CP. Hemato-critical issues in quantitative analysis of dried blood spots: challenges and solutions. Bioanalysis 2013;5:2023–41.10.4155/bio.13.156Suche in Google Scholar PubMed

36. Lelubre C, Vincent JL. Red blood cell transfusion in the critically ill patient. Ann Intensive Care 2011;1:43.10.1186/2110-5820-1-43Suche in Google Scholar PubMed PubMed Central

37. Afshar M, Burnham EL, Joyce C, Clark BJ, Yong M, Gaydos J, et al. Cut-point levels of phosphatidylethanol to identify alcohol misuse in a mixed cohort including critically ill patients. Alcohol Clin Exp Res 2017;41:1745–53.10.1111/acer.13471Suche in Google Scholar PubMed PubMed Central

38. Leuthold LA, Heudi O, Déglon J, Raccuglia M, Augsburger M, Picard F, et al. New microfluidic-based sampling procedure for overcoming the hematocrit problem associated with dried blood spot analysis. Anal Chem 2015;87:2068–71.10.1021/ac503931gSuche in Google Scholar PubMed

39. Capiau S, Stove VV, Lambert WE, Stove CP. Prediction of the hematocrit of dried blood spots via potassium measurement on a routine clinical chemistry analyzer. Anal Chem 2013;85:404–10.10.1021/ac303014bSuche in Google Scholar PubMed

40. Capiau S, Wilk LS, Aalders MC, Stove CP. A novel, nondestructive, dried blood spot-based hematocrit prediction method using noncontact diffuse reflectance spectroscopy. Anal Chem 2016;88:6538–46.10.1021/acs.analchem.6b01321Suche in Google Scholar PubMed

Received: 2018-06-26
Accepted: 2018-09-09
Published Online: 2018-10-11
Published in Print: 2019-04-24

©2019 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Cardiac biomarkers – 2019
  4. Reviews
  5. Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice
  6. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review
  7. Opinion Papers
  8. Detection capability of quantitative faecal immunochemical tests for haemoglobin (FIT) and reporting of low faecal haemoglobin concentrations
  9. Should phosphatidylethanol be currently analysed using whole blood, dried blood spots or both?
  10. IFCC Papers
  11. High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers
  12. Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB)
  13. Genetics and Molecular Diagnostics
  14. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation
  15. General Clinical Chemistry and Laboratory Medicine
  16. Commutable whole blood reference materials for hemoglobin A1c validated on multiple clinical analyzers
  17. When results matter: reliable creatinine concentrations in hyperbilirubinemia patients
  18. Mass spectrometry based analytical quality assessment of serum and plasma specimens with patterns of endo- and exogenous peptides
  19. Association of serum sphingomyelin profile with clinical outcomes in patients with lower respiratory tract infections: results of an observational, prospective 6-year follow-up study
  20. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants
  21. Hematology and Coagulation
  22. Commutability assessment of reference materials for the enumeration of lymphocyte subsets
  23. Circulating platelet-neutrophil aggregates as risk factor for deep venous thrombosis
  24. Reference Values and Biological Variations
  25. A comparison of complete blood count reference intervals in healthy elderly vs. younger Korean adults: a large population study
  26. Indirect determination of hematology reference intervals in adult patients on Beckman Coulter UniCell DxH 800 and Abbott CELL-DYN Sapphire devices
  27. Cancer Diagnostics
  28. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer
  29. Cardiovascular Diseases
  30. Sample matrix and high-sensitivity cardiac troponin I assays
  31. Preoperative proteinuria and clinical outcomes in type B aortic dissection after thoracic endovascular aortic repair
  32. Infectious Diseases
  33. The rational specimen for the quantitative detection of Epstein-Barr virus DNA load
  34. Letters to the Editor
  35. Letter to the Editor on article Dimech W, Karakaltsas M, Vincini G. Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing. Clin Chem Lab Med 2018;56:1970–8
  36. Counterpoint to the Letter to the Editor by Badrick and Parvin in regard to Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing
  37. Is creatine kinase an ideal biomarker in rhabdomyolysis? Reply to Lippi et al.: Diagnostic biomarkers of muscle injury and exertional rhabdomyolysis (https://doi.org/10.1515/cclm-2018-0656)
  38. Blood neuron cell-derived microparticles as potential biomarkers in Alzheimer’s disease
  39. A fast, nondestructive, low-cost method for the determination of hematocrit of dried blood spots using image analysis
  40. Association of fibroblast growth factor 21 plasma levels with neonatal sepsis: preliminary results
  41. Impact of continuous renal replacement therapy (CRRT) and other extracorporeal support techniques on procalcitonin guided antibiotic therapy in critically ill patients with septic shock
  42. Determining the cutoff value of the APTT mixing test for factor VIII inhibitor
  43. Determining the cut-off value of the APTT mixing test for factor VIII inhibitor: reply
  44. Euthyroid Graves’ disease with spurious hyperthyroidism: a diagnostic challenge
  45. A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories
  46. MS-based proteomics: a metrological sound and robust alternative for apolipoprotein E phenotyping in a multiplexed test
https://doi.org/10.1515/cclm-2018-0667
Schlagwörter für diesen Artikel
alcohol; dried blood spot; phosphatidylethanol; whole blood

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Cardiac biomarkers – 2019
  4. Reviews
  5. Current understanding and future directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice
  6. Serum cytokines, adipokines and ferritin for non-invasive assessment of liver fibrosis in chronic liver disease: a systematic review
  7. Opinion Papers
  8. Detection capability of quantitative faecal immunochemical tests for haemoglobin (FIT) and reporting of low faecal haemoglobin concentrations
  9. Should phosphatidylethanol be currently analysed using whole blood, dried blood spots or both?
  10. IFCC Papers
  11. High sensitivity, contemporary and point-of-care cardiac troponin assays: educational aids developed by the IFCC Committee on Clinical Application of Cardiac Bio-Markers
  12. Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB)
  13. Genetics and Molecular Diagnostics
  14. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation
  15. General Clinical Chemistry and Laboratory Medicine
  16. Commutable whole blood reference materials for hemoglobin A1c validated on multiple clinical analyzers
  17. When results matter: reliable creatinine concentrations in hyperbilirubinemia patients
  18. Mass spectrometry based analytical quality assessment of serum and plasma specimens with patterns of endo- and exogenous peptides
  19. Association of serum sphingomyelin profile with clinical outcomes in patients with lower respiratory tract infections: results of an observational, prospective 6-year follow-up study
  20. Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging anticoagulants
  21. Hematology and Coagulation
  22. Commutability assessment of reference materials for the enumeration of lymphocyte subsets
  23. Circulating platelet-neutrophil aggregates as risk factor for deep venous thrombosis
  24. Reference Values and Biological Variations
  25. A comparison of complete blood count reference intervals in healthy elderly vs. younger Korean adults: a large population study
  26. Indirect determination of hematology reference intervals in adult patients on Beckman Coulter UniCell DxH 800 and Abbott CELL-DYN Sapphire devices
  27. Cancer Diagnostics
  28. Large platelet size is associated with poor outcome in patients with metastatic pancreatic cancer
  29. Cardiovascular Diseases
  30. Sample matrix and high-sensitivity cardiac troponin I assays
  31. Preoperative proteinuria and clinical outcomes in type B aortic dissection after thoracic endovascular aortic repair
  32. Infectious Diseases
  33. The rational specimen for the quantitative detection of Epstein-Barr virus DNA load
  34. Letters to the Editor
  35. Letter to the Editor on article Dimech W, Karakaltsas M, Vincini G. Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing. Clin Chem Lab Med 2018;56:1970–8
  36. Counterpoint to the Letter to the Editor by Badrick and Parvin in regard to Comparison of four methods of establishing control limits for monitoring quality controls in infectious disease serology testing
  37. Is creatine kinase an ideal biomarker in rhabdomyolysis? Reply to Lippi et al.: Diagnostic biomarkers of muscle injury and exertional rhabdomyolysis (https://doi.org/10.1515/cclm-2018-0656)
  38. Blood neuron cell-derived microparticles as potential biomarkers in Alzheimer’s disease
  39. A fast, nondestructive, low-cost method for the determination of hematocrit of dried blood spots using image analysis
  40. Association of fibroblast growth factor 21 plasma levels with neonatal sepsis: preliminary results
  41. Impact of continuous renal replacement therapy (CRRT) and other extracorporeal support techniques on procalcitonin guided antibiotic therapy in critically ill patients with septic shock
  42. Determining the cutoff value of the APTT mixing test for factor VIII inhibitor
  43. Determining the cut-off value of the APTT mixing test for factor VIII inhibitor: reply
  44. Euthyroid Graves’ disease with spurious hyperthyroidism: a diagnostic challenge
  45. A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories
  46. MS-based proteomics: a metrological sound and robust alternative for apolipoprotein E phenotyping in a multiplexed test
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 14.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/cclm-2018-0667/html
Button zum nach oben scrollen